| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 代理产品(元) | 41,891,053.48 | 113,817,053.59 | 57,502,444.42 |
| 活性原料(元) | 6,402,497.28 | 22,756,753.08 | 13,330,287.05 |
| 疫苗(元) | 171,733,366.31 | 606,432,558.89 | 525,603,747.32 |
| 诊断试剂(元) | 565,687,526.74 | - | 724,141,690.64 |
| 诊断仪器(元) | 41,969,465.54 | - | 31,925,635.27 |
| 试剂(元) | - | 1,433,300,032.38 | - |
| 仪器(元) | - | 38,784,375.51 | - |
| 营业成本(元) | |||
| 代理产品(元) | 20,733,757.98 | 50,273,673.43 | 31,260,858.10 |
| 活性原料(元) | 2,322,237.75 | 2,232,504.44 | 1,022,478.71 |
| 疫苗(元) | 70,278,177.70 | 179,306,715.39 | 157,586,097.82 |
| 诊断试剂(元) | 163,307,027.09 | - | 136,585,945.36 |
| 诊断仪器(元) | 70,285,033.02 | - | 33,724,806.85 |
| 试剂(元) | - | 351,758,714.62 | - |
| 仪器(元) | - | 159,233,721.51 | - |
| 毛利(元) | |||
| 代理产品(元) | 21,157,295.50 | 63,543,380.16 | 26,241,586.32 |
| 活性原料(元) | 4,080,259.53 | 20,524,248.64 | 12,307,808.34 |
| 疫苗(元) | 101,455,188.61 | 427,125,843.50 | 368,017,649.50 |
| 诊断试剂(元) | 402,380,499.65 | - | 587,555,745.28 |
| 诊断仪器(元) | -28,315,567.48 | - | -1,799,171.58 |
| 试剂(元) | - | 1,081,541,317.76 | - |
| 仪器(元) | - | -120,449,346.00 | - |
| 毛利率(%) | |||
| 代理产品(%) | 50.51 | 55.83 | 45.64 |
| 活性原料(%) | 63.73 | 90.19 | 92.33 |
| 疫苗(%) | 59.08 | 70.43 | 70.02 |
| 诊断试剂(%) | 71.13 | - | 81.14 |
| 诊断仪器(%) | -67.47 | - | -5.64 |
| 试剂(%) | - | 75.46 | - |
| 仪器(%) | - | -310.56 | - |
| 收入构成(%) | |||
| 代理产品(%) | 5.06 | 5.14 | 4.25 |
| 活性原料(%) | 0.77 | 1.03 | 0.99 |
| 疫苗(%) | 20.75 | 27.38 | 38.86 |
| 诊断试剂(%) | 68.35 | - | 53.54 |
| 诊断仪器(%) | 5.07 | - | 2.36 |
| 试剂(%) | - | 64.71 | - |
| 仪器(%) | - | 1.75 | - |
| 毛利构成(%) | |||
| 代理产品(%) | 4.23 | 4.32 | 2.64 |
| 活性原料(%) | 0.81 | 1.39 | 1.24 |
| 疫苗(%) | 20.26 | 29.01 | 37.09 |
| 诊断试剂(%) | 80.35 | - | 59.21 |
| 诊断仪器(%) | -5.65 | - | -0.18 |
| 试剂(%) | - | 73.46 | - |
| 仪器(%) | - | -8.18 | - |